Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published:April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like Study uncovers why white button mushrooms may help prevent prostate cancer progression November 12, 2024 SCD health disparities tied to community factors October 8, 2024 Progressive and anti-abortion? New group plays fast and loose to make points November 27, 2023
Study uncovers why white button mushrooms may help prevent prostate cancer progression November 12, 2024